

A Current Review of Pediatric Endocrinology
May 2-4, 2007
Toronto, Ontario, Canada

- 2-1/2 days, 23 speakers, 230 learners, no commercial exhibitors, no posters presented.
- Learner type: 87% Physicians, 4% Nurses, 1% Pharmacists, 2% Research Scientists, 6% Other
- 3% of learners had attended this meeting in a prior year.
- Credit type: ACCME
- This conference addressed advances in the pathophysiology, molecular biology, diagnosis and management of endocrine disorders. The faculty addressed topics including thyroid disease, growth, puberty, endocrine disruptors, calcium metabolism, bone disease, diabetes and obesity.
- 99% of learners reported that the content was free from commercial bias.
- 89% of learners reported that the content was scientifically rigorous.
- 97% of learners reported that they would recommend this program to a colleague.
- Objectives of the course were to:
 - Describe the pathogenesis, diagnosis and management of a wide range of endocrine disorders.
 - Describe endocrine sequelae of other diseases and their treatments.
 - Explain the laboratory testing used in endocrine disorders.
- Selected learner comments included:
 - “This is an excellent course – I will highly recommend it.”
 - “It provides a comprehensive overview of information, important.”
 - “Good overview of pediatric endocrinology.”
 - “Comprehensive – appropriate length talks – program content and timing well planned – great review.”
 - “Excellent lectures, well organized, bargain for the price.”
 - “Would recommend – wide range of pediatric endocrinology talks, chance to collaborate with colleagues.”
 - “Focus some time on treatment.”
 - “Add more case presentations.”
 - “More focused on board review.”
 - “There was sufficient time to interact with speakers and it was also well organized.”
 - “Good variety of experts and lecture topics.”
- Selected comments about the speakers included:
 - “Very clear presentation – all relevant information.”
 - “Made a dry topic interesting.”
 - “Very appropriate summarization of recent studies for board review.”
 - “Extremely informative, entertaining and engaging presentation.”
 - “Extremely knowledgeable.”
 - “Lots of information for me to review.”
 - “Very thorough, well presented.”
 - “Well organized – helped me to understand topic.”
 - “Very well presented for difficult topic.”
 - “Clear, thorough – well explained – also incorporated new data and genetics – would highly recommend again.”
 - “Very nice summary with good review.”

- “Difficult topic made clear and succinct.”
- “Excellent – great data.”
- “An outstanding talk – good review of complicated topic – I like that he discussed workup and specifics of treatment.”
- “Excellent presentation of immunology related to endocrine conditions.”
- “Nicely done – good review of the science of obesity.”
- “Good use of evidence/data.”

Disclosure of Faculty Relationships

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA), the Accreditation Council for Pharmaceutical Education (ACPE), and all other professional organizations as applicable, stating that programs where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

As uses for pharmaceutical agents, medical devices, and other products may be presented in the program that are not necessarily the same as those indicated in approved product labeling (but which may reflect clinical experience, professional literature, other clinical sources known to the presenter, or investigational uses of products), we ask the presenter to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is *not* intended to exclude faculty who have relationships with such companies; it is simply intended to inform participants of any potential conflicts so that participants may form their own judgments based on full disclosure of the facts. Further, these opinions and recommendations presented during the program or materials related to the program do not imply an endorsement or recommendation on the part of BioSymposia, Inc. These presentations solely represent the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-FDA approved (off-label) uses of drugs:

David Allen, M.D. discloses he is the recipient of research grants from Genentech and Pfizer.

Philippe Backeljauw, M.D. discloses he will discuss the off-label use of products approved for adults and used in the treatment of the pediatric population.

Laurie Cohen, M.D. discloses she is the recipient of honoraria from Novo-Nordisk.

Linda DiMeglio, M.D., M.P.H. discloses she will discuss the off-label use of medications (e.g., bisphosphonates) used for the treatment of pediatric osteoporosis.

George Eisenbarth, M.D., Ph.D. discloses he is a diabetes consultant for MacroGenics, and he is also a consultant for Bayhill Therapeutics and receives stock options from Bayhill Therapeutics.

Georgeanna Klingensmith, M.D. discloses she is a consultant for Abbott, and her presentation will include off-label information on the use of continuous glucose sensors in the pediatric population.

Joseph Majzoub, M.D. discloses he will include off-label discussion of the use of oral and subcutaneous desmopressin.

Jon Nakamoto, M.D., Ph.D. discloses he is an employee of Quest Diagnostics Nichols Institute.

Mark Palmert, M.D., Ph.D. discloses he will include off-label discussion of the use of leuprolide in diagnostic testing and off-label treatment of precocious puberty with hitrelin.

Stephen Ponder, M.D., F.A.A.P., C.D.E. discloses he is a consultant for Diabetech, Inc. and spoke at an Animas meeting.

Ron Rosenfeld, M.D. discloses he is a consultant for Tercica and has received honoraria and research grant funding from Tercica. He also discloses he is a consultant and has received honoraria from Genentech, Lilly, Novo-Nordisk, and Pfizer.

William Russell, M.D. discloses he was a consultant for Pfizer in 2005.

William Winter, M.D. discloses he is a member of the Athena Diagnostics speaker's bureau. He is the Medical Director of the Diagnostic Referral Laboratory, Endocrine Autoantibody Laboratory at the University of Gainesville in Florida.

The following faculty indicated no significant relationship with commercial supporters and/or discussion of investigational or non-FDA approved (off-label) uses of drugs:

Craig Alter, M.D., Bruce Boston, M.D., Thomas Carpenter, M.D., John Fuqua, M.D., Catherine Gordon, M.D., M.Sc., Stephen Huang, M.D., Mary Lee, M.D., Todd Nebesio, M.D., Sally Radovick, M.D., Surendra Varma, M.D., Joseph Wolfsdorf, M.B., B.Ch.

Commercial Support and Other Disclosures

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) is a 501(c)3 non-profit organization. All of our programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers and do not represent an endorsement or recommendation on the part of BioSymposia, Inc.

This program was supported by an unrestricted educational grant from EMD Serono, Inc. In addition, BioSymposia personnel are employees of EMD Serono, Inc. and BioSymposia, Inc. also receives other in-kind support from EMD Serono, Inc. in the form of space and administrative services.